




RealRate

PHARMACEUTICAL 2019

ANI Pharmaceuticals INC
Rank 188 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ANI Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANI Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 74% points. The greatest weakness of ANI Pharmaceuticals INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 6.7% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	152,877
Cost of Goods Sold	73,024
Intangible Assets	205,184
Liabilities, Current	165,549
Liabilities, Non-Current	67,792
Other Assets	34,453
Other Compr. Net Income	-379
Other Expenses	38,299
Other Liabilities	0
Other Net Income	-15,308
Other Revenues	201,576
Property and Equipment	38,090
Research and Development	15,388
Selling, General and Administrative Expense	44,063

Output Variable	Value in 1000 USD
Assets	430,604
Liabilities	233,341
Expenses	170,774
Revenues	201,576
Stockholders Equity	197,263
Net Income	15,494
Comprehensive Net Income	15,304
BaseVar	525,991
ECR before LimitedLiability	134%
Economic Capital Ratio	256%